- Home
- CATO vs ANL Comparison
CATO vs ANL Comparison
Compare CATO & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CATO | ANL |
|---|---|---|
| Founded | 1946 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 350.9M |
| IPO Year | 1994 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CATO | ANL |
|---|---|---|
| Price | $2.97 | $8.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 48.1K | ★ 214.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.09 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $649,806,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.92 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.19 | $0.88 |
| 52 Week High | $4.92 | $12.09 |
Technical Indicators
Market Signals| Indicator | CATO | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 44.76 | 55.38 |
| Support Level | $2.81 | $1.37 |
| Resistance Level | $3.22 | $10.15 |
| Average True Range (ATR) | 0.18 | 0.97 |
| MACD | 0.00 | -0.27 |
| Stochastic Oscillator | 17.31 | 56.12 |
Price Performance
Historical ComparisonAbout CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.